MARKET WIREYahoo! Finance Canada • 1d ago
Immutep Limited (IMMP) Stock Price, News, Quote & HistoryYahoo! Finance Canada report covering Immutep Limited (IMMP) market action, institutional positioning, and fundamental catalysts.
Why IMMP Stock advanced +0.33% Today — RQD Quant Desk Flash
$3.07 +0.33% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $3.07
Immutep Limited (IMMP) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $22.6M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on IMMP Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is IMMP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Immutep Limited (NASDAQ: IMMP) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $3.07 (+0.33% 1D, market cap $22.6M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, IMMP ranks #315 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does IMMP compare to MIRA and QNRX in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IMMP carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, MIRA (MIRA Pharmaceuticals Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $23.0M) and QNRX (Quoin Pharmaceuticals Ltd.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $21.8M). Among the 5-stock peer group, IMMP leads on earnings multiple (N/A) while MIRA leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for IMMP?
▼
For Immutep Limited (IMMP), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #315 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $3.07 (-0.13%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-4.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IMMP)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (47/100 Composite)
🔍 WHY IMMP SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)
SEC XBRL Trailing 12 Months: 0% FCF Margin ($631.5K FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$3.57-8.7% Next Q
55
Q2 (-2Q)Grade C-$3.26-3.4% Next Q
52
Q3 (-1Q)Grade C-$3.15-2.5% Next Q
50
CurrentGrade D$3.07-5.9% Hist 90D α
47
Trajectory: C (55) → D (47)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a IMMP Turnaround Squeeze
While IMMP currently carries a cautious 47/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.07) and Max Pain ($3.22) forces dealer call-delta covering toward $67.83.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $IMMP• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IMMP Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why IMMP Stock advanced +0.33% Today — RQD Quant Desk Flash
Immutep Limited (IMMP) advanced +0.33% to $3.07, trading at 2% of its 52-week range ($1.65 – $64.6). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($1.65 – $64.6) with RSI-14 at 29.5 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $3.07 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $631509 annual free cash flow.
Live IMMP Headlines & Catalysts
MARKET WIREStock Titan • 1d ago
Nasdaq closed Immutep's listing case after 10 business days meeting the $1 bid minimum.Stock Titan report covering Immutep Limited (IMMP) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Immutep Announces Late-Breaking Abstract on IMP761 Accepted for Poster Presentation at ACR Convergence 2026Yahoo Finance report covering Immutep Limited (IMMP) market action, institutional positioning, and fundamental catalysts.
RISK WATCHStock Titan • 1d ago
Immutep Limited (IMMP) EPS 2025: $0.03 loss per shareStock Titan report covering Immutep Limited (IMMP) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026Yahoo Finance report covering Immutep Limited (IMMP) market action, institutional positioning, and fundamental catalysts.
MARKET WIREKalkine Media • 1d ago
Immutep FY2026 Annual Report Reveals ADS Ratio Increase to 200 SharesKalkine Media report covering Immutep Limited (IMMP) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Immutep Limited (IMMP) Total Assets 2025: $103.2M, down 23.3%Stock Titan report covering Immutep Limited (IMMP) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Immutep and Monash University Secure Further ARC Linkage Projects Funding for LAG-3 ResearchYahoo Finance report covering Immutep Limited (IMMP) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 5d ago
Immutep Quarterly Activities Report Q1 FY27Media Release Immutep intends to focus the registration-directed clinical development of efti on HNSCC in patients with CPS <1 and the neoadjuvant setting of STS, with preparations for future clinical trials underway and
MARKET WIREBenzinga • 5d ago
Immutep Refocuses Efti Development On HNSCC, Soft Tissue Sarcoma; New Trial Starts Targeted For H2 2027Immutep intends to focus the registration-directed clinical development of efti on HNSCC in patients with CPS <1 and the neoadjuvant setting of STS, with preparations for future clinical trials underway and study
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IMMP)
- ✓Walkthrough of IMMP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
IMMP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -66.63%▼ DESCENDING CHANNEL
2026-11-03O $3.33H $3.33L $3.06C $3.07VOL 10.6K
RES: $7.32SUP: $2.02SMA50: $5.07SMA200: $16.39
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
IMMP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on IMMP today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for IMMP. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IMMP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IMMP)
Health Care Rank #315 of 1015
⚔️ MIRA vs IMMP Full Matrix →
1. Head-to-Head Health Care Peer Comparison (IMMP vs. MIRA, QNRX, ATOS, CRVO)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Immutep Limited (IMMP) ranks #315 by composite RQD confidence (47/100, grade D) and #822 by equity capitalization ($22.6M). Within this direct 5-issuer industry benchmark cohort, IMMP leads on earnings valuation at N/A trailing P/E, while MIRA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. IMMP currently leads its immediate peer cohort in composite quantitative strength at 47/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IMMP
ACTIVE
Immutep Limited | D | 47/100 | — | — | — | +0.33% | $22.6M | Benchmark Subject |
| MIRA MIRA Pharmaceuticals Inc. | D- | 36/100 | — | — | -35.0% | -2.06% | $23.0M | /mira-vs-immp → |
| QNRX Quoin Pharmaceuticals Ltd. | D- | 37/100 | — | — | -35.0% | -11.45% | $21.8M | /qnrx-vs-immp → |
| ATOS Atossa Therapeutics Inc. | E | 33/100 | — | — | -35.0% | +5.99% | $21.7M | /atos-vs-immp → |
| CRVO CervoMed Inc. | E | 28/100 | — | — | -35.0% | +2.50% | $24.2M | /crvo-vs-immp → |
2. IMMP Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTImmutep Limited (IMMP) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $22.6M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
3. IMMP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs IMMP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Immutep Limited (NASDAQ: IMMP) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $3.07 (+0.33% 1D, market cap $22.6M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, IMMP ranks #315 in composite RQD confidence.
How does IMMP compare to MIRA and QNRX in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IMMP carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, MIRA (MIRA Pharmaceuticals Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $23.0M) and QNRX (Quoin Pharmaceuticals Ltd.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $21.8M). Among the 5-stock peer group, IMMP leads on earnings multiple (N/A) while MIRA leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for IMMP?
For Immutep Limited (IMMP), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #315 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is IMMP trading relative to its 50-day, 200-day, and 52-week technical levels?
IMMP last traded at $3.07 (+0.33% on volume of 11,631 shares), positioning the stock -39.45% below its 50-day simple moving average ($5.07) and -81.27% below its 200-day simple moving average ($16.39). Across its 52-week range of $1.65 to $64.60, IMMP sits at the 2.3% percentile with a 14-day RSI of 29.5 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($2.69 to $3.45).
ROARABLE RATING BRIEF • RQD 47/100 (D)
✓ SEC XBRL & RQD VERIFIED
IMMP — Immutep Limited: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03
1. Roarable Rating Brief: What This Means to a Prospective Investor
Immutep Limited (IMMP) earns a live Roarable RQD composite score of 47/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $3.07 (+0.33% 1D, market capitalization $22.6M).
- Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
- Whale 13F & Options Flow (3/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (10/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Immutep Limited (IMMP) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. Its market capitalization is $0.0B.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D • RQD 47/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.65 – $64.60 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
The Butterfly Supply-Chain Graph lists the supply chain as NONE, with no upstream or downstream links and no sector-correlation data. The source data therefore does not identify upstream dependencies, downstream customers, or second-order bottlenecks for IMMP. Investors should monitor the clinical and regulatory catalysts noted in the news wire, as these represent the only explicitly identified forward-looking items.
- Key Question #1: Can IMMP sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $64.60 52-week high?
- Key Question #3: How sensitive is IMMP's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
IMMP Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Immutep Limited (IMMP) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago
Immutep Limited (IMMP) Stock Price, News, Quote & History Yahoo! Finance Canada report covering Immutep Limited (IMMP) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Nasdaq closed Immutep's listing case after 10 business days meeting the $1 bid minimum. Stock Titan report covering Immutep Limited (IMMP) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Immutep Announces Late-Breaking Abstract on IMP761 Accepted for Poster Presentation at ACR Convergence 2026 Yahoo Finance report covering Immutep Limited (IMMP) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Stock Titan • 1d ago
Immutep Limited (IMMP) EPS 2025: $0.03 loss per share Stock Titan report covering Immutep Limited (IMMP) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026 Yahoo Finance report covering Immutep Limited (IMMP) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Kalkine Media • 1d ago
Immutep FY2026 Annual Report Reveals ADS Ratio Increase to 200 Shares Kalkine Media report covering Immutep Limited (IMMP) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Immutep Limited (IMMP) Total Assets 2025: $103.2M, down 23.3% Stock Titan report covering Immutep Limited (IMMP) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Immutep and Monash University Secure Further ARC Linkage Projects Funding for LAG-3 Research Yahoo Finance report covering Immutep Limited (IMMP) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
IMMP Bull vs. Bear Conversation Board — What's Your Call at $3.07?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IMMP 🐻 33% BEARISH CONVICTION
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH
🎯 Target: $4.01 (+31.0%)
📌 Pinned Debate The Forensic Balance Sheet pillar scores 13 of 20 with Altman Z at 2.5, the strongest pillar relative to the others.
Don't sleep on IMMP's setup in Health Care. The Forensic Balance Sheet pillar scores 13 of 20 with Altman Z at 2.5, the strongest pillar relative to the others.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (47/100) backs up the fundamental quality.
ArenaChamp_24 🐂 BULL
@SkepticalCFA Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.
SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH
🎯 Target: $2.63 (-14.1%)
Spot @ $3.06 The Whale 13F Flow pillar scores 3 of 20 and ROIC and FCF yield are both 0%, leaving no cash-generation or institutional-sponsorship su
Fading this rally in IMMP at $3.06. The Whale 13F Flow pillar scores 3 of 20 and ROIC and FCF yield are both 0%, leaving no cash-generation or institutional-sponsorship support.. With a beta of 1.0 and the stock sitting at $3.06 (52-wk range $1.65–$64.60), the easy multiple expansion is already priced in.